| Active substance | Belumosudil |
| Holder | Sanofi |
| Status | Running |
| Indication | chronic Graft Versus Host Disease (cGVHD) after failure of at least 2 prior lines of systemic therapy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 07/11/2024 |